Valuation : VERE THER

Market Cap 99Cr 86Cr 81Cr 74Cr 137.91Cr 9.5TCr 138.61Cr 963.26Cr 370.42Cr 4.83TCr 373.36Cr 365.17Cr 15TCr P/E 2023
-4.47x
P/E 2024 -2.4x
Enterprise Value 54Cr 47Cr 44Cr 40Cr 75Cr 5.16TCr 75Cr 523.08Cr 201.15Cr 2.62TCr 202.74Cr 198.3Cr 8.29TCr EV / Sales 2023
4,64,30,598x
EV / Sales 2024 7,17,743x
Free-Float
-
Yield 2023 *
-
Yield 2024 -
3 years 2.86
Extreme 2.8647
20.12
5 years 2.86
Extreme 2.8647
71.04
10 years 2.86
Extreme 2.8647
78
Manager TitleAgeSince
President - 25/07/2025
Date Insider Type Main position Quantity % Market Cap. Importance
25/07/25 Tender

Chief Technology Officer

5,38,331 0.6358%
25/07/25 Tender

Chief Administrative Officer

5,34,066 0.6308%
25/07/25 Tender

Founder

33,97,141 4.0125%

Financials

2023 2024
Net sales 11.76 10.13 9.59 8.69 16.31 1.12T 16.39 113.93 43.81 571.49 44.16 43.19 1.81T 32.33 27.86 26.38 23.91 44.85 3.09T 45.08 313.28 120.47 1.57T 121.43 118.76 4.97T
Net income -20Cr -17Cr -16Cr -15Cr -28Cr -1.91TCr -28Cr -193.85Cr -75Cr -972.41Cr -75Cr -73Cr -3.07TCr -20Cr -17Cr -16Cr -15Cr -28Cr -1.9TCr -28Cr -192.54Cr -74Cr -965.81Cr -75Cr -73Cr -3.05TCr
Net Debt -55Cr -47Cr -45Cr -41Cr -76Cr -5.25TCr -77Cr -531.99Cr -204.57Cr -2.67TCr -206.2Cr -201.67Cr -8.43TCr -45Cr -39Cr -37Cr -34Cr -63Cr -4.34TCr -63Cr -440.19Cr -169.27Cr -2.21TCr -170.62Cr -166.87Cr -6.98TCr
Logo VERE THER
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.
Employees
274
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. VERV Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!